Contact us

Turning to nutrition to help address the complications of prematurity

Since 2012, the American Academy of Pediatrics has recommended an exclusive human-milk diet in the NICU.1 When Prolacta products are used as a part of that EHMD2 as compared to cow milk-based fortifiers, our nutritional products are clinically proven for critically ill, extremely premature infants in the NICU weighing 500-1,250 g at birth to:

  • Improve health outcomes3,4,5,6,7,8
  • Improve growth rates7,9
  • Reduce hospital costs6,10

Prolacta remains the only company providing human milk-based, human milk fortifiers throughout the world today. And from day one to today, we’ve always followed the highest levels of quality and safety.

Getting the most out of an EHMD

Clinical value

Learn about cost savings, complication reductions, and health outcomes associated with our products

Clinical evidence

Read peer-reviewed studies and clinical results

Peer support

Gain insights from fellow neonatologists, nurses, and dietitians

Leading the human milk industry in quality and safety

nursing

First and only pharmaceutical-grade manufacturing facilities for the testing and processing of human milk

vile

Exceed food-product industry requirements by following stringent quality and safety standards based on those for the human plasma and blood industry

FDA-regulated lab processes

Our human milk laboratory and manufacturing processes are regulated by the U.S. Food and Drug Administration (FDA).

All Prolacta nutritional products are pasteurized to ensure the highest quality and safety, using time and temperature profiles defined by the FDA in its Pasteurized Milk Ordinance (PMO) to destroy pathogenic viruses and bacteria.

While there are other pasteurization and sterilization processes used in the human milk banking industry, only products manufactured with our pasteurization process are clinically proven to improve health and reduce complications when used as part of an EHMD in the neonatal intensive care unit (NICU). There is no clinical data showing similar results using products processed by any other method.

Benefits of HMOs

Prolacta’s 100% human milk–based products contain a wide spectrum of human milk oligosaccharides (HMOs).11 The immunity, prebiotic, and gut maturation benefits that HMOs promote may have a role in the health outcomes attributed to an EHMD, including Prolacta’s products.12

To learn more

Improving health outcomes for premature infants

For more than two decades, we have been advancing the science of human milk to improve the health of premature and critically ill infants worldwide.

  • More than 63,000 fragile premature infants throughout the world have benefited from our proven human milk–based nutritional products
  • The clinical benefits of our products have been demonstrated in 20+ clinical trials studying 5,000+ infants

A cost-effective solution

When used as part of an EHMD, our nutritional products are clinically proven to increase survival and reduce the overall cost of care compared to cow milk–based fortifiers or preterm formula in extremely premature infants.5,6

Tell us how we can help

Clinician-to-clinician guidance

Coding, billing, and reimbursement questions

Finding my sales representative

Support with an order

Citations